Weighted Average Number of Shares Outstanding, Diluted of Viracta Therapeutics, Inc. from 31 Mar 2011 to 30 Sep 2024

Taxonomy & unit
us-gaap: shares
Description
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
Summary
Viracta Therapeutics, Inc. quarterly and annual Weighted Average Number of Shares Outstanding, Diluted in shares history and change rate from 31 Mar 2011 to 30 Sep 2024.
  • Viracta Therapeutics, Inc. Weighted Average Number of Shares Outstanding, Diluted for the quarter ending 30 Sep 2024 was 39,574,070, a 2.3% increase year-over-year.
  • Viracta Therapeutics, Inc. annual Weighted Average Number of Shares Outstanding, Diluted for 2023 was 38,624,462, a 2.2% increase from 2022.
  • Viracta Therapeutics, Inc. annual Weighted Average Number of Shares Outstanding, Diluted for 2022 was 37,790,981, a 19% increase from 2021.
  • Viracta Therapeutics, Inc. annual Weighted Average Number of Shares Outstanding, Diluted for 2021 was 31,870,067.
Source SEC data
View on sec.gov
Weighted Average Number of Shares Outstanding, Diluted, Quarterly (shares)
Weighted Average Number of Shares Outstanding, Diluted, YoY Quarterly Change (%)
Weighted Average Number of Shares Outstanding, Diluted, Annual (shares)
Weighted Average Number of Shares Outstanding, Diluted, YoY Annual Change (%)

Viracta Therapeutics, Inc. Quarterly Weighted Average Number of Shares Outstanding, Diluted (shares)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2024 39,574,070 +890,212 +2.3% 01 Jul 2024 30 Sep 2024 10-Q 13 Nov 2024 2024 Q3
Q2 2024 39,404,975 +844,599 +2.2% 01 Apr 2024 30 Jun 2024 10-Q 14 Aug 2024 2024 Q2
Q1 2024 39,323,964 +865,127 +2.2% 01 Jan 2024 31 Mar 2024 10-Q 09 May 2024 2024 Q1
Q4 2023 38,624,462 +833,481 +2.2% 01 Oct 2023 31 Dec 2023 10-K 07 Mar 2024 2023 FY
Q3 2023 38,683,858 +978,341 +2.6% 01 Jul 2023 30 Sep 2023 10-Q 13 Nov 2024 2024 Q3
Q2 2023 38,560,376 +961,132 +2.6% 01 Apr 2023 30 Jun 2023 10-Q 14 Aug 2024 2024 Q2
Q1 2023 38,458,837 +922,963 +2.5% 01 Jan 2023 31 Mar 2023 10-Q 09 May 2024 2024 Q1
Q4 2022 37,790,981 01 Oct 2022 31 Dec 2022 10-K 07 Mar 2024 2023 FY
Q3 2022 37,705,517 01 Jul 2022 30 Sep 2022 10-Q 09 Nov 2023 2023 Q3
Q2 2022 37,599,244 01 Apr 2022 30 Jun 2022 10-Q 14 Aug 2023 2023 Q2
Q1 2022 37,535,874 01 Jan 2022 31 Mar 2022 10-Q 09 May 2023 2023 Q1
Q4 2017 31,667,000 +12,382,000 +64% 01 Oct 2017 31 Dec 2017 10-K 09 Mar 2018 2017 FY
Q3 2017 23,678,000 +9,175,000 +63% 01 Jul 2017 30 Sep 2017 10-K 09 Mar 2018 2017 FY
Q2 2017 21,521,000 +7,028,000 +48% 01 Apr 2017 30 Jun 2017 10-K 09 Mar 2018 2017 FY
Q1 2017 21,029,000 +6,586,000 +46% 01 Jan 2017 31 Mar 2017 10-K 09 Mar 2018 2017 FY
Q4 2016 19,285,000 +6,504,000 +51% 01 Oct 2016 31 Dec 2016 10-K 09 Mar 2018 2017 FY
Q3 2016 14,503,000 +2,040,000 +16% 01 Jul 2016 30 Sep 2016 10-K 09 Mar 2018 2017 FY
Q2 2016 14,493,000 +2,405,000 +20% 01 Apr 2016 30 Jun 2016 10-K 09 Mar 2018 2017 FY
Q1 2016 14,443,000 +3,169,000 +28% 01 Jan 2016 31 Mar 2016 10-K 09 Mar 2018 2017 FY
Q4 2015 12,781,000 -50,260,000 -80% 01 Oct 2015 31 Dec 2015 10-K 09 Mar 2017 2016 FY
Q3 2015 12,463,000 -48,086,000 -79% 01 Jul 2015 30 Sep 2015 10-K 09 Mar 2017 2016 FY
Q2 2015 12,088,000 -49,807,000 -80% 01 Apr 2015 30 Jun 2015 10-K 09 Mar 2017 2016 FY
Q1 2015 11,274,000 -45,039,000 -80% 01 Jan 2015 31 Mar 2015 10-K 09 Mar 2017 2016 FY
Q4 2014 63,041,000 +7,468,000 +13% 01 Oct 2014 31 Dec 2014 10-K 14 Mar 2016 2015 FY
Q3 2014 60,549,000 +7,278,000 +14% 01 Jul 2014 30 Sep 2014 10-K 14 Mar 2016 2015 FY
Q2 2014 61,895,000 +8,627,000 +16% 31 Mar 2014 30 Jun 2014 10-Q 30 Jul 2015 2015 Q2
Q1 2014 56,313,000 +4,726,000 +9.2% 01 Jan 2014 31 Mar 2014 10-K 14 Mar 2016 2015 FY
Q4 2013 55,573,000 +2,725,000 +5.2% 01 Oct 2013 31 Dec 2013 10-K 12 Mar 2015 2014 FY
Q3 2013 53,271,000 +5,873,000 +12% 01 Jul 2013 30 Sep 2013 10-K 12 Mar 2015 2014 FY
Q2 2013 53,268,000 +5,982,000 +13% 01 Apr 2013 30 Jun 2013 10-K 12 Mar 2015 2014 FY
Q1 2013 51,587,000 +4,794,000 +10% 01 Jan 2013 31 Mar 2013 10-K 12 Mar 2015 2014 FY
Q4 2012 52,848,000 +6,115,000 +13% 01 Oct 2012 31 Dec 2012 10-K 06 Mar 2014 2013 FY
Q3 2012 47,398,000 +684,000 +1.5% 01 Jul 2012 30 Sep 2012 10-K 06 Mar 2014 2013 FY
Q2 2012 47,286,000 +991,000 +2.1% 01 Apr 2012 30 Jun 2012 10-K 06 Mar 2014 2013 FY
Q1 2012 46,793,000 -1,073,000 -2.2% 01 Jan 2012 31 Mar 2012 10-K 06 Mar 2014 2013 FY
Q4 2011 46,733,000 01 Oct 2011 31 Dec 2011 10-K 13 Mar 2013 2012 FY
Q3 2011 46,714,000 01 Jul 2011 30 Sep 2011 10-K 13 Mar 2013 2012 FY
Q2 2011 46,295,000 01 Apr 2011 30 Jun 2011 10-K 13 Mar 2013 2012 FY
Q1 2011 47,866,000 01 Jan 2011 31 Mar 2011 10-K 13 Mar 2013 2012 FY

Viracta Therapeutics, Inc. Annual Weighted Average Number of Shares Outstanding, Diluted (shares)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2023 38,624,462 +833,481 +2.2% 01 Jan 2023 31 Dec 2023 10-K 07 Mar 2024 2023 FY
2022 37,790,981 +5,920,914 +19% 01 Jan 2022 31 Dec 2022 10-K 07 Mar 2024 2023 FY
2021 31,870,067 01 Jan 2021 31 Dec 2021 10-K 14 Mar 2023 2022 FY
2017 24,516,000 +8,828,000 +56% 01 Jan 2017 31 Dec 2017 10-K 09 Mar 2018 2017 FY
2016 15,688,000 +3,532,000 +29% 01 Jan 2016 31 Dec 2016 10-K 09 Mar 2018 2017 FY
2015 12,156,000 +1,904,000 +19% 01 Jan 2015 31 Dec 2015 10-K 09 Mar 2018 2017 FY
2014 10,252,000 -41,997,000 -80% 01 Jan 2014 31 Dec 2014 10-K 09 Mar 2017 2016 FY
2013 52,249,000 +4,103,000 +8.5% 01 Jan 2013 31 Dec 2013 10-K 14 Mar 2016 2015 FY
2012 48,146,000 01 Jan 2012 31 Dec 2012 10-K 12 Mar 2015 2014 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.